{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:04Z","timestamp":1793140684055,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UNIVERSITY GLOBAL PARTNERSHIP NETWORK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00406-019-00982-6","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T09:09:03Z","timestamp":1548925743000},"page":"121-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Is cannabidiol the ideal drug to treat non-motor Parkinson\u2019s disease symptoms?"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-6746","authenticated-orcid":false,"given":"Jos\u00e9 Alexandre S.","family":"Crippa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio W.","family":"Zuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor","family":"Tumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael G.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"982_CR1","volume-title":"Neurological disorders: public health challenges","author":"World Health Organization (WHO)","year":"2006","unstructured":"World Health Organization (WHO) (2006) Neurological disorders: public health challenges. WHO Press, Geneva"},{"key":"982_CR2","doi-asserted-by":"publisher","first-page":"18781","DOI":"10.3390\/molecules191118781","volume":"19","author":"S Giacoppo","year":"2014","unstructured":"Giacoppo S, Mandolino G, Galuppo M et al (2014) Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 19:18781\u201318816","journal-title":"Molecules"},{"key":"982_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0002","volume":"2","author":"M Stampanoni Bassi","year":"2017","unstructured":"Stampanoni Bassi M, Sancesario A, Morace R et al (2017) Cannabinoids in Parkinson\u2019s disease. Cannabis Cannabinoid Res 2:21\u201329","journal-title":"Cannabis Cannabinoid Res"},{"key":"982_CR4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fj.14.10.1432","volume":"14","author":"V Marzo Di","year":"2000","unstructured":"Di Marzo V, Hill MP, Bisogno T et al (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson\u2019s disease. FASEB J 14:1432\u20131438","journal-title":"FASEB J"},{"key":"982_CR5","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","volume":"14","author":"I Lastres-Becker","year":"2001","unstructured":"Lastres-Becker I, Cebeira M, de Ceballos ML et al (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827\u20131832","journal-title":"Eur J Neurosci"},{"key":"982_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1006\/exnr.2001.7649","volume":"169","author":"MA Silverdale","year":"2001","unstructured":"Silverdale MA, McGuire S, McInnes A et al (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson\u2019s disease. Exp Neurol 169:400\u2013406","journal-title":"Exp Neurol"},{"key":"982_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","volume":"3","author":"JM Brotchie","year":"2003","unstructured":"Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson\u2019s disease. Curr Opin Pharmacol 3:54\u201361","journal-title":"Curr Opin Pharmacol"},{"key":"982_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.brainresbull.2012.02.012","volume":"87","author":"S Farkas","year":"2012","unstructured":"Farkas S, Nagy K, Jia Z et al (2012) The decrease of dopamine D2\/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson\u2019s disease: a preliminary autoradiographic study with the selective dopamine D2\/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015. Brain Res Bull 87:504\u2013510","journal-title":"Brain Res Bull"},{"key":"982_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","volume":"64","author":"Y G\u00f3mez-G\u00e1lvez","year":"2016","unstructured":"G\u00f3mez-G\u00e1lvez Y, Palomo-Garo C, Fern\u00e1ndez-Ruiz J et al (2016) Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 64:200\u2013208","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"982_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/exnr.1997.6645","volume":"148","author":"YP Maneuf","year":"1997","unstructured":"Maneuf YP, Crossman AR, Brotchie JM (1997) The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson\u2019s disease. Exp Neurol 148:265\u2013270","journal-title":"Exp Neurol"},{"key":"982_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/mds.10289","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Henry B, Hill M et al (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 17:1180\u20131187","journal-title":"Mov Disord"},{"key":"982_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.brainres.2005.04.010","volume":"1046","author":"S Gonz\u00e1lez","year":"2005","unstructured":"Gonz\u00e1lez S, Mena MA, Lastres-Becker I et al (2005) Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 1046:195\u2013206","journal-title":"Brain Res"},{"key":"982_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","volume":"19","author":"I Lastres-Becker","year":"2005","unstructured":"Lastres-Becker I, Molina-Holgado F, Ramos J et al (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease. Neurobiol Dis 19:96\u2013107","journal-title":"Neurobiol Dis"},{"key":"982_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1124\/jpet.107.125666","volume":"323","author":"X Cao","year":"2007","unstructured":"Cao X, Liang L, Hadcock JR et al (2007) Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 323:318\u2013326","journal-title":"J Pharmacol Exp Ther"},{"key":"982_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","volume":"208","author":"MG Morgese","year":"2007","unstructured":"Morgese MG, Cassano T, Cuomo V et al (2007) Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors. Exp Neurol 208:110\u2013119","journal-title":"Exp Neurol"},{"key":"982_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neulet.2008.04.041","volume":"438","author":"M Garc\u00eda-Arencibia","year":"2008","unstructured":"Garc\u00eda-Arencibia M, Ferraro L, Tanganelli S et al (2008) Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438:10\u201313","journal-title":"Neurosci Lett"},{"key":"982_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.euroneuro.2007.11.003","volume":"18","author":"SA Vliet van","year":"2008","unstructured":"van Vliet SA, Vanwersch RA, Jongsma MJ et al (2008) Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol 18:383\u2013389","journal-title":"Eur Neuropsychopharmacol"},{"key":"982_CR18","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","volume":"29","author":"DA Price","year":"2009","unstructured":"Price DA, Martinez AA, Seillier A et al (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Eur J Neurosci 29:2177\u20132186","journal-title":"Eur J Neurosci"},{"key":"982_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.brainres.2010.09.086","volume":"1363","author":"S Walsh","year":"2010","unstructured":"Walsh S, Gorman AM, Finn DP et al (2010) The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. Brain Res 1363:40\u201348","journal-title":"Brain Res"},{"key":"982_CR20","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","volume":"187","author":"YC Chung","year":"2011","unstructured":"Chung YC, Bok E, Huh SH et al (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187:6508\u20136517","journal-title":"J Immunol"},{"key":"982_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","volume":"163","author":"C Garc\u00eda","year":"2011","unstructured":"Garc\u00eda C, Palomo-Garo C, Garc\u00eda-Arencibia M et al (2011) Symptom-relieving and neuroprotective effects of the phytocannabinoid \u22069-THCV in animal models of Parkinson\u2019s disease. Br J Pharmacol 163:1495\u20131506","journal-title":"Br J Pharmacol"},{"key":"982_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","volume":"38","author":"CB Carroll","year":"2012","unstructured":"Carroll CB, Zeissler ML, Hanemann CO et al (2012) \u22069-tetrahydrocannabinol (\u22069-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson\u2019s disease. Neuropathol Appl Neurobiol 38:535\u2013547","journal-title":"Neuropathol Appl Neurobiol"},{"key":"982_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neures.2011.12.006","volume":"72","author":"A Martinez","year":"2012","unstructured":"Martinez A, Macheda T, Morgese MG et al (2012) The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res 72:236\u2013242","journal-title":"Neurosci Res"},{"key":"982_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/FBP.0000000000000004","volume":"24","author":"AL Guti\u00e9rrez-Valdez","year":"2013","unstructured":"Guti\u00e9rrez-Valdez AL, Garc\u00eda-Ruiz R, Anaya-Mart\u00ednez V et al (2013) The combination of oral L-DOPA\/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Behav Pharmacol 24:640\u2013652","journal-title":"Behav Pharmacol"},{"key":"982_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1586\/14737175.2014.985209","volume":"14","author":"SR Benbadis","year":"2014","unstructured":"Benbadis SR, Sanchez-Ramos J, Bozorg A et al (2014) Medical marijuana in neurology. Expert Rev Neurother 14:1453\u20131465","journal-title":"Expert Rev Neurother"},{"key":"982_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JC, Fife T et al (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82:1556\u20131563","journal-title":"Neurology"},{"key":"982_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s13311-015-0367-5","volume":"12","author":"S Arjmand","year":"2015","unstructured":"Arjmand S, Vaziri Z, Behzadi M et al (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12:778\u2013787","journal-title":"Neurotherapeutics"},{"key":"982_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11940-015-0370-5","volume":"17","author":"B Catlow","year":"2015","unstructured":"Catlow B, Sanchez-Ramos J (2015) Cannabinoids for the treatment of movement disorders. Curr Treat Options Neurol 17:370","journal-title":"Curr Treat Options Neurol"},{"key":"982_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-20825-1_8","volume":"231","author":"J Fern\u00e1ndez-Ruiz","year":"2015","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Ramos J (2015) Endocannabinoids and neurodegenerative disorders: Parkinson\u2019s disease, Huntington\u2019s chorea, Alzheimer\u2019s disease, and others. Handb Exp Pharmacol 231:233\u2013259","journal-title":"Handb Exp Pharmacol"},{"key":"982_CR30","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"KA Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M et al (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111","journal-title":"Neurology"},{"key":"982_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mds.1280","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Kellett M, Moore AP et al (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145\u2013149","journal-title":"Mov Disord"},{"key":"982_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PG, Teare L et al (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250","journal-title":"Neurology"},{"key":"982_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","volume":"27","author":"V Mesnage","year":"2004","unstructured":"Mesnage V, Houeto JL, Bonnet AM et al (2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 27:108\u2013110","journal-title":"Clin Neuropharmacol"},{"key":"982_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/mds.20111","volume":"19","author":"K Venderov\u00e1","year":"2004","unstructured":"Venderov\u00e1 K, R\u016fzicka E, Vor\u00edsek V et al (2004) Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 19:1102\u20131106","journal-title":"Mov Disord"},{"key":"982_CR35","first-page":"6","volume":"874849","author":"TA Finseth","year":"2015","unstructured":"Finseth TA, Hedeman JL, Brown RP 2nd et al (2015) Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson\u2019s disease patients in Colorado. Evid Based Complement Altern Med 874849:6","journal-title":"Evid Based Complement Altern Med"},{"key":"982_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","volume":"40","author":"Y Balash","year":"2017","unstructured":"Balash Y, Bar-Lev Schleider L, Korczyn AD et al (2017) Medical cannabis in Parkinson disease: real-life patients\u2019 experience. Clin Neuropharmacol 40:268\u2013272","journal-title":"Clin Neuropharmacol"},{"key":"982_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","volume":"37","author":"I Lotan","year":"2014","unstructured":"Lotan I, Treves TA, Roditi Y et al (2014) Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 37:41\u201344","journal-title":"Clin Neuropharmacol"},{"key":"982_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","volume":"1134","author":"M Garc\u00eda-Arencibia","year":"2007","unstructured":"Garc\u00eda-Arencibia M, Gonz\u00e1lez S, de Lago E et al (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162\u2013170","journal-title":"Brain Res"},{"key":"982_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-130050","volume":"35","author":"MJ Casarejos","year":"2013","unstructured":"Casarejos MJ, Perucho J, Gomez A et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35:525\u2013539","journal-title":"J Alzheimers Dis"},{"key":"982_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","volume":"46","author":"FV Gomes","year":"2013","unstructured":"Gomes FV, Del Bel EA, Guimaraes FS (2013) Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry 46:43\u201347","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"982_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","volume":"94","author":"M -Santos-Pereira dos","year":"2016","unstructured":"dos-Santos-Pereira M, da-Silva CA, Guimar\u00e3es FS et al (2016) Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 94:179\u2013195","journal-title":"Neurobiol Dis"},{"key":"982_CR42","first-page":"343","volume":"7","author":"FF Peres","year":"2016","unstructured":"Peres FF, Levin R, Suiama MA et al (2016) Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front Pharmacol 7:343","journal-title":"Front Pharmacol"},{"key":"982_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JA, Hallak JE et al (2009) Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol 23:979\u2013983","journal-title":"J Psychopharmacol"},{"key":"982_CR44","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131098","journal-title":"J Psychopharmacol"},{"key":"982_CR45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/jcpt.12179","volume":"39","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Eckeli AL, Zuardi AW et al (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther 39:564\u2013566","journal-title":"J Clin Pharm Ther"},{"key":"982_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41398-018-0162-2","volume":"8","author":"B Vanle","year":"2018","unstructured":"Vanle B, Olcott W, Jimenez J et al (2018) NMDA antagonists for treating the non-motor symptoms in Parkinson\u2019s disease. Transl Psychiatry 8:117","journal-title":"Transl Psychiatry"},{"key":"982_CR47","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.2174\/138161212802884681","volume":"18","author":"AW Zuardi","year":"2012","unstructured":"Zuardi AW, Crippa JA, Hallak JE et al (2012) A critical review of the antipsychotic effects of cannabidiol: 30\u00a0years of a translational investigation. Curr Pharm Des 18:5131\u20135140","journal-title":"Curr Pharm Des"},{"key":"982_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","volume":"24","author":"CD Schubart","year":"2014","unstructured":"Schubart CD, Sommer IE, Fusar-Poli P et al (2014) Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 24:51\u201364","journal-title":"Eur Neuropsychopharmacol"},{"key":"982_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","volume":"162","author":"TA Iseger","year":"2015","unstructured":"Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162:153\u2013161","journal-title":"Schizophr Res"},{"key":"982_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2016.05.013","volume":"80","author":"M Fakhoury","year":"2016","unstructured":"Fakhoury M (2016) Could cannabidiol be used as an alternative to antipsychotics? J Psychiatr Res 80:14\u201321","journal-title":"J Psychiatr Res"},{"key":"982_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.schres.2016.06.022","volume":"176","author":"A Gururajan","year":"2016","unstructured":"Gururajan A, Malone DT (2016) Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res 176:281\u2013290","journal-title":"Schizophr Res"},{"key":"982_CR52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.lfs.2004.01.015","volume":"75","author":"VM Guimar\u00e3es","year":"2004","unstructured":"Guimar\u00e3es VM, Zuardi AW, Del Bel EA et al (2004) Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 75:633\u2013638","journal-title":"Life Sci"},{"key":"982_CR53","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"982_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231","journal-title":"Am J Psychiatry"},{"key":"982_CR55","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/S1516-4446(12)70057-0","volume":"34","author":"AR Schier","year":"2012","unstructured":"Schier AR, Ribeiro NP, Silva AC et al (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr 34:S104\u2013S110","journal-title":"Rev Bras Psiquiatr"},{"key":"982_CR56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J et al (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836","journal-title":"Neurotherapeutics"},{"key":"982_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","volume":"39","author":"NE Zlebnik","year":"2016","unstructured":"Zlebnik NE, Cheer JF (2016) Beyond the CB1 receptor: is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci 39:1\u201317","journal-title":"Annu Rev Neurosci"},{"key":"982_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1570159X14666160509123955","volume":"15","author":"VP Soares","year":"2017","unstructured":"Soares VP, Campos AC (2017) Evidences for the anti-panic actions of cannabidiol. Curr Neuropharmacol 15:291\u2013299","journal-title":"Curr Neuropharmacol"},{"key":"982_CR59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG et al (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82\u201388","journal-title":"J Psychopharmacol"},{"key":"982_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA Crippa","year":"2004","unstructured":"Crippa JA, Zuardi AW, Garrido GE et al (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417\u2013426","journal-title":"Neuropsychopharmacology"},{"key":"982_CR61","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774","journal-title":"Neuropsychopharmacology"},{"key":"982_CR62","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL et al (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259","journal-title":"Front Pharmacol"},{"key":"982_CR63","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Chagas MH et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219\u20131226","journal-title":"Neuropsychopharmacology"},{"key":"982_CR64","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA, Derenusson GN, Ferrari TB et al (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25:121\u2013130","journal-title":"J Psychopharmacol"},{"key":"982_CR65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S2045796018000239","volume":"27","author":"GM Mandolini","year":"2018","unstructured":"Mandolini GM, Lazzaretti M, Pigoni A et al (2018) Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci 27:327\u2013335","journal-title":"Epidemiol Psychiatr Sci"},{"key":"982_CR66","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0269881112474524","volume":"27","author":"MH Chagas","year":"2013","unstructured":"Chagas MH, Crippa JA, Zuardi AW et al (2013) Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol 27:312\u2013316","journal-title":"J Psychopharmacol"},{"key":"982_CR67","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","volume":"18","author":"PJ Gates","year":"2014","unstructured":"Gates PJ, Albertella L, Copeland J (2014) The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev 18:477\u2013487","journal-title":"Sleep Med Rev"},{"key":"982_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2174\/1570159X11666131204235805","volume":"12","author":"E Murillo-Rodr\u00edguez","year":"2014","unstructured":"Murillo-Rodr\u00edguez E, S\u00e1nchez D, Tejeda-Padr\u00f3n A et al (2014) Potential effects of cannabidiol as a wake-promoting agent. Curr Neuropharmacol 12:269\u2013272","journal-title":"Curr Neuropharmacol"},{"key":"982_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","volume":"19","author":"KA Babson","year":"2017","unstructured":"Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 19:23","journal-title":"Curr Psychiatry Rep"},{"key":"982_CR70","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/B978-0-12-800756-3.00106-X","volume-title":"Handbook of cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment","author":"IMP Linares","year":"2017","unstructured":"Linares IMP, Crippa JAS, Chagas MHN (2017) Beneficial effects of cannabis and related compounds on sleep. In: Preedy V (ed) Handbook of cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment, 1st\u00a0edn. Academic Press, London, pp\u00a0877\u2013882","edition":"1"},{"key":"982_CR71","doi-asserted-by":"publisher","first-page":"S417","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","volume":"21","author":"EA Carlini","year":"1981","unstructured":"Carlini EA, Cunha JM (1981) Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21:S417\u2013S427","journal-title":"J Clin Pharmacol"},{"key":"982_CR72","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A et al (2018) No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol 9:315","journal-title":"Front Pharmacol"},{"key":"982_CR73","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.jcp.0000125688.05091.8f","volume":"24","author":"AN Nicholson","year":"2004","unstructured":"Nicholson AN, Turner C, Stone BM et al (2004) Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24:305\u2013313","journal-title":"J Clin Psychopharmacol"},{"key":"982_CR74","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fphar.2018.00482","volume":"9","author":"FF Peres","year":"2018","unstructured":"Peres FF, Lima AC, Hallak JEC et al (2018) Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol 9:482","journal-title":"Front Pharmacol"},{"key":"982_CR75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fphar.2017.00269","volume":"8","author":"AC Campos","year":"2017","unstructured":"Campos AC, Foga\u00e7a MV, Scarante FF et al (2017) Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol 8:269","journal-title":"Front Pharmacol"},{"key":"982_CR76","doi-asserted-by":"publisher","first-page":"582","DOI":"10.2174\/138955711795906905","volume":"11","author":"JP Little","year":"2011","unstructured":"Little JP, Villanueva EB, Klegeris A (2011) Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson\u2019s disease. Mini Rev Med Chem 11:582\u2013590","journal-title":"Mini Rev Med Chem"},{"key":"982_CR77","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"M Bergamaschi","year":"2011","unstructured":"Bergamaschi M, Queiroz RH, Zuardi AW et al (2011) Safety and side effects of cannabidiol, a Cannabis sativa. Curr Drug Saf 6:237\u2013249","journal-title":"Curr Drug Saf"},{"key":"982_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"I Kerstin","year":"2017","unstructured":"Kerstin I, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154","journal-title":"Cannabis Cannabinoid Res"},{"key":"982_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C et al (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21\u201334","journal-title":"Cannabis Cannabinoid Res"},{"key":"982_CR80","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2008.12.004","volume":"141","author":"AG Beiske","year":"2009","unstructured":"Beiske AG, Loge JH, Ronningen A et al (2009) Pain in Parkinson\u2019s disease: prevalence and characteristics. Pain 141:173\u2013177","journal-title":"Pain"},{"key":"982_CR81","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/mds.22142","volume":"23","author":"L N\u00e8gre-Pag\u00e8s","year":"2008","unstructured":"N\u00e8gre-Pag\u00e8s L, Regragui W, Bouhassira D et al (2008) Chronic pain in Parkinson\u2019s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361\u20131369","journal-title":"Mov Disord"},{"key":"982_CR82","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S et al (2010) Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord 25:1646\u20131651","journal-title":"Mov Disord"},{"key":"982_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.06.001","author":"MA Silverdale","year":"2018","unstructured":"Silverdale MA, Kobylecki C, Kass-Iliyya L et al (2018) A detailed clinical study of pain in 1957 participants with early\/moderate Parkinson\u2019s disease. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"982_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","volume":"556","author":"B Costa","year":"2007","unstructured":"Costa B, Trovato AE, Comelli F et al (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556:75\u201383","journal-title":"Eur J Pharmacol"},{"key":"982_CR85","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1213\/ANE.0b013e3182283486","volume":"113","author":"SJ Ward","year":"2011","unstructured":"Ward SJ, Ramirez MD, Neelakantan H et al (2011) Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female c57bl6 mice. Anesth Analg 113:947\u2013950","journal-title":"Anesth Analg"},{"key":"982_CR86","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fphar.2017.00391","volume":"8","author":"K Genaro","year":"2017","unstructured":"Genaro K, Fabris D, Arantes ALF et al (2017) Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats. Front Pharmacol 8:391","journal-title":"Front Pharmacol"},{"key":"982_CR87","first-page":"CD012182","volume":"3","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L et al (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182","journal-title":"Cochrane Database Syst Rev"},{"key":"982_CR88","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.transproceed.2017.12.042","volume":"50","author":"L Cu\u00f1etti","year":"2018","unstructured":"Cu\u00f1etti L, Manzo L, Peyraube R et al (2018) Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc 50:461\u2013464","journal-title":"Transplant Proc"},{"key":"982_CR89","unstructured":"Howick J, Chalmers I, Glasziou P et al (2011) The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebm.net\/index.aspx?o=5653 . Accessed 31 July 2018"},{"key":"982_CR90","doi-asserted-by":"publisher","first-page":"k2827","DOI":"10.1136\/bmj.k2827","volume":"361","author":"J Wise","year":"2018","unstructured":"Wise J (2018) FDA approves its first cannabis based medicine. BMJ 361:k2827","journal-title":"BMJ"},{"key":"982_CR91","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Philips JA (2018) A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 3:152\u2013161","journal-title":"Cannabis Cannabinoid Res"},{"key":"982_CR92","doi-asserted-by":"publisher","first-page":"587","DOI":"10.15585\/mmwr.mm6720a5","volume":"67","author":"RZ Horth","year":"2018","unstructured":"Horth RZ, Crouch B, Horowitz BZ et al (2018) Notes from the field: acute poisonings from a synthetic cannabinoid sold as cannabidiol\u2014Utah, 2017\u20132018. MMWR Morb Mortal Wkly Rep 67:587\u2013588","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-019-00982-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-00982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-00982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T21:27:09Z","timestamp":1606339629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-019-00982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s00406-019-00982-6","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"15 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JAC, JH, FSG, and AWZ are co-inventors (Mechoulam R, Crippa JA, Guimaraes FS, Zuardi A, Hallak, JE, and Breuer A) of the patent \u201cFluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO\/2014\/108899. International Application No.: PCT\/IL2014\/050023\u201d Def. US no. Reg. 62193296; 29\/07\/2015; INPI on 19\/08\/2015 (BR1120150164927). The University of S\u00e3o Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of S\u00e3o Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil) to \u201cdevelop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson\u2019s disease, and anxiety disorders\u201d. JAC and JEH have received travel support from and are medical advisors of BSPG-Pharm. JAC has a Grant from University Global Partnership Network (UGPN)\u2014Global priorities in cannabinoid research excellence. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}